China Automotive Systems' Fully Redundant AP04 EPS Platform Meets ASPICE 4.0 CL2 in Joint Assessment by European OEM and UL

China Automotive Systems (NASDAQ: CAAS) reported unaudited results for the first six months ended June 30, 2026. Net sales rose 20.1% to $412.5 million. Net income attributable to common shareholders increased 98.8% to $29.3 million, and diluted EPS rose 98.0% to $0.97. Cash and pledged cash were $155.6 million. The company said EPS sales grew 32.2% to $192.9 million and won EPS contracts for South America with mass production expected in early 2028.

China Automotive Systems, Inc. (CAAS) furnished an SEC Form 6-K — earnings release. Exhibit 99.1 China Automotive Systems Record Earnings Per Share Rose 98% in the First Half of 2026 WUHAN, China, August 13, 2026 -- China Automotive Systems, Inc. (NASDAQ: CAAS) (“CAAS” or the “Company”), a leading power steering components and systems supplier in China, today an

HubSpot, a business software company, is cutting 7% of its workforce (660 jobs) as part of a restructuring to streamline operations and focus on AI-driven outcomes. The move is not tied to AI efficiencies or cost-cutting, according to CEO Yamini Rangan. Despite the layoffs, HubSpot reported a 20% revenue increase to $911.7M in Q2 2026 and reaffirmed its guidance. The restructuring is expected to cost $65M-$75M, with most charges in Q4 2026.

Avolon ordered 250 aircraft from Boeing (140 737 MAX) and Airbus (110 A320neo/A330neo). The deal, pending shareholder approval, increases Avolon's firm commitments to 749. Airbus highlights strong demand for its aircraft.

Merck (MRK) reported that its investigational drug, remigromig, met the primary endpoint of non-inferiority in visual acuity compared to ranibizumab in a trial for diabetic macular edema. The BRUNELLO trial enrolled 984 participants, with mean visual acuity gains of 9.1 and 8.7 letters for remigromig doses, versus 11.8 for ranibizumab. Adverse events were higher with remigromig. Merck plans to discuss the results with regulators.

The U.S. Navy plans to contract Lockheed Martin to integrate the Long Range Anti-Ship Missile (LRASM) on B-52 bombers. The contract includes software updates, testing, and repairs. The B-52 can potentially carry up to 20 LRASMs, similar to its current missile capacity. According to retired Air Force Col. Mark Gunzinger, this integration will enhance maritime strike capabilities. Lockheed Martin declined further comment, referring to the Pentagon.